File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: LB80380: A promising new drug for the treatment of chronic Hepatitis B

TitleLB80380: A promising new drug for the treatment of chronic Hepatitis B
Authors
Issue Date2008
PublisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/eid
Citation
Expert Opinion On Investigational Drugs, 2008, v. 17 n. 10, p. 1581-1588 How to Cite?
AbstractHepatitis B virus is a significant cause of liver cirrhosis and hepatocellular carcinoma in patients with chronic infection. Higher levels of viral load are associated with increased risk of developing liver-related complications. The current available oral therapies suppress viral replication through their action on the hepatitis B virus polymerase. As treatment with oral nucleoside/nucleotide analogues is associated with the development of drug-resistant mutations, there is continuing research for newer and more potent antiviral agents to reduce the chance of drug resistance. LB80380, a prodrug, is an oral nucleotide analogue that inhibits viral replication by incorporation into the viral DNA. Antiviral activity against wild-type virus and virus with drug-resistant mutations was demonstrated in Phase II trials, with significant reduction of viral load in patients treated with LB80380. LB80380 was also shown to be safe and well tolerated. © 2008 Informa UK Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/163205
ISSN
2015 Impact Factor: 4.408
2015 SCImago Journal Rankings: 1.314
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorFung, Jen_US
dc.contributor.authorLai, CLen_US
dc.contributor.authorYuen, MFen_US
dc.date.accessioned2012-09-05T05:28:44Z-
dc.date.available2012-09-05T05:28:44Z-
dc.date.issued2008en_US
dc.identifier.citationExpert Opinion On Investigational Drugs, 2008, v. 17 n. 10, p. 1581-1588en_US
dc.identifier.issn1354-3784en_US
dc.identifier.urihttp://hdl.handle.net/10722/163205-
dc.description.abstractHepatitis B virus is a significant cause of liver cirrhosis and hepatocellular carcinoma in patients with chronic infection. Higher levels of viral load are associated with increased risk of developing liver-related complications. The current available oral therapies suppress viral replication through their action on the hepatitis B virus polymerase. As treatment with oral nucleoside/nucleotide analogues is associated with the development of drug-resistant mutations, there is continuing research for newer and more potent antiviral agents to reduce the chance of drug resistance. LB80380, a prodrug, is an oral nucleotide analogue that inhibits viral replication by incorporation into the viral DNA. Antiviral activity against wild-type virus and virus with drug-resistant mutations was demonstrated in Phase II trials, with significant reduction of viral load in patients treated with LB80380. LB80380 was also shown to be safe and well tolerated. © 2008 Informa UK Ltd.en_US
dc.languageengen_US
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/eiden_US
dc.relation.ispartofExpert Opinion on Investigational Drugsen_US
dc.subject.meshAdenine - Analogs & Derivatives - Therapeutic Useen_US
dc.subject.meshAlanine Transaminase - Blooden_US
dc.subject.meshAntiviral Agents - Therapeutic Useen_US
dc.subject.meshDna, Viral - Blooden_US
dc.subject.meshGuanine - Adverse Effects - Analogs & Derivatives - Pharmacology - Therapeutic Useen_US
dc.subject.meshHepatitis B E Antigens - Blooden_US
dc.subject.meshHepatitis B, Chronic - Drug Therapyen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunologic Factors - Therapeutic Useen_US
dc.subject.meshPhosphonic Acids - Adverse Effects - Pharmacology - Therapeutic Useen_US
dc.subject.meshPractice Guidelines As Topicen_US
dc.titleLB80380: A promising new drug for the treatment of chronic Hepatitis Ben_US
dc.typeArticleen_US
dc.identifier.emailFung, J:jfung@sicklehut.comen_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.emailYuen, MF:mfyuen@hkucc.hku.hken_US
dc.identifier.authorityFung, J=rp00518en_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.identifier.authorityYuen, MF=rp00479en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1517/13543784.17.10.1581en_US
dc.identifier.pmid18808318-
dc.identifier.scopuseid_2-s2.0-52949101763en_US
dc.identifier.hkuros158453-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-52949101763&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume17en_US
dc.identifier.issue10en_US
dc.identifier.spage1581en_US
dc.identifier.epage1588en_US
dc.identifier.isiWOS:000260080000016-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridFung, J=23091109300en_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US
dc.identifier.scopusauthoridYuen, MF=7102031955en_US
dc.identifier.citeulike3353037-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats